anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI\<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
An order information recording unit records information on an order for a patient. An arrival state recording unit records an arrival state that indicates whether or not a patient has arrived, in association with an order for the patient. An accepting unit accepts patient identification information entered into a portable terminal device. An order retrieval unit retrieves an order related to the patient identification information accepted by the accepting unit. A decision processing unit decides to display an entry screen for medical interview information when the arrival state associated with an order related to the patient identification information indicates that the patient has arrived. A display processing unit displays the entry screen for the medical interview information on the portable terminal device, in response to the decision made by the decision processing unit.
DL1 will consist of cladribine 5mg/m2 IV once daily on days 1-3, cytarabine 20mg/m2 IV daily days 1-5, and tagraxofusp 12 mcg/kg IV daily days 4-6. If a DLT is encountered in the first 2 participants, 3 more will be enrolled at the same dose.
The process for developing Adapted TranS-C has been iterative and grounded in theory, data and stakeholder feedback. The core elements of the evidence-based theory of change underpinning TranS-C have been retained. Adapted TranS-C is delivered in four 20-minute, weekly, individual sessions and is comprised of 4 cross-cutting interventions featured in every session, 5 modules that apply to the vast majority of patients, and 1 optional module used less commonly, depending on the presentation.
Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely with great frequency and the anticoagulant dose should be adjusted accordingly (see Boxed WARNING and CLINICAL PHARMACOLOGY). Altered coagulation parameters and/or bleeding have been reported in patients taking XELODA concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon. These events occurred within several days and up to several months after initiating XELODA therapy and, in a few cases, within 1 month after stopping XELODA. These events occurred in patients with and without liver metastases. In a drug interaction study with single-dose warfarin administration, there was a significant increase in the mean AUC of S-warfarin. The maximum observed INR value increased by 91%. This interaction is probably due to an inhibition of cytochrome P450 2C9 by capecitabine and/or its metabolites (see CLINICAL PHARMACOLOGY).
Antibodies are retargeted to a target for which they have no functional specificity under normal circumstances. Use is made of a multi-specific binding substance which has binding specificity for the target and anti-antibody binding specificity. The binding substance may comprise an immunoglobulin antigen binding site and may be a "diabody". Depending on the antibody bound, effector functions such as Complement, ADCC and immune blocking are recruited to act on the target. Example targets are human cells. In vivo and in vitro utilities are exemplified, including lysis of tumor cells and agglutination of red blood cells.
BACKGROUND: POLIII-related leukodystrophies are a group of recently recognized hereditary white matter diseases with a similar clinical and radiological phenotype. No Tunisian studies have been published about POLIII-related leukodystrophy due to POLR3A variants. The aim of this study was to contribute to the clinical, radiological, and genetic characterization of POLR3A-related leukodystrophy in a Tunisian cohort.
METHODS: We report six cases of genetically confirmed POLR3A-related leukodystrophy belonging to six unrelated Tunisian families, along with a review of previously published pediatric cases.
RESULTS: All patients were born to consanguineous marriages and originated from the North or the Center of Tunisia. Age at onset varied between 15 months and 6 years. The clinical phenotype was similar in all patients with cerebellar ataxia, tremor, and nystagmus being the key features. Brain imaging showed diffuse hypomyelination in all patients with progressive cerebellar atrophy in three patients. Molecular analysis identified the same bi-allelic NM_007055.4:c.2011T>C; p.(Trp671Arg) variant in the POLR3A gene in all patients.
CONCLUSION: We hypothesize a founder effect for the identified variant given its recurrence in six unrelated individuals with a similar clinical phenotype. Given the apparent genetic homogeneity of Tunisian POLR3A patients, the recurrent variant should be directly targeted. This should facilitate diagnosis in index patients, and genetic counseling.
A method, system, and device for selective power saving may be used in medical procedures. The device may be configured to receive motion information from a detector and location information from a sensor. A processor may correlate the motion information and the location information to determine whether to maintain power to the sensor. The determination of whether to maintain power to the sensor may be based on the correlation of the motion information and the location information. The processor may determine whether the location of the device has changed and the degree of that change. The processor may also determine whether the motion information is less than a duration threshold. The duration threshold may be a user configurable threshold. The processor may power off the sensor if a duration threshold is met and/or the location of the wireless tool has not changed.
Diseases mediated by cytokine storms are often characterized by an overexuberant pace of pathogenesis accompanied by significant morbidity and mortality. Thus, near real-time (NRT) detections via a site-of-inflammation (SOI) sampling of proinflammatory cytokines are essential to ensure a timely and effective treatment of acute inflammations, which up to now, has not been fully possible. In this work, we proposed a novel NRT and SOI immunosensor using ZIF-8 signal amplification together with an off-on strategy. To achieve NRT detections via a SOI sampling, the body fluid of choice is the dermal interstitial fluid (ISF). The significant merits of ISF over blood are the quality, quantity and diversity of ISF-based biomarkers; the fluid is non-coagulating, making it feasible to perform multiple or continuous samplings and the sampling is minimally invasive. Our immunosensor requires only 5 μL of ISF to achieve a simultaneous detection of five highly potent proinflammatory cytokines: IL-6, IFN-γ, IL-1β, TNF-α, IP-10. We employed a microneedle array patch (MAP) together with a trifurcated nozzle pump to extract a mean volume of between 30 and 60 μL of ISF in 20 min. Under optimal conditions, the biosensor is capable of high-quality performance that exhibits a lower limit of detection (LOD) of 5.761 pg/mL over a wide linear range of 5.761-3 ‒ 20.00 ng/mL. We believe our immunosensor for NRT detections via a SOI sampling of ISF-biomarkers offers new theranostic opportunities that may not be possible with blood-based biomarkers.
PROBLEM TO BE SOLVED: To obtain a pharmaceutical preparation for application to skin capable of formulating a drug unstable in a base in a stable state, excellent in storage stability and usable by a simple method. SOLUTION: This pharmaceutical preparation for application to skin is obtained by forming a drug layer and a base layer reactive with the drug in a separated state on a tacky tape and integrating the drug layer with the base layer at the time of the application to the skin for use. A supporting sheet 5 containing the drug (or a base) is placed on the tacky tape 4 and a container 2 prepared by filling the base (or the drug) 6 in a solution state therein and sealing the container 2 with a breakable sheet 3 is then placed thereon. The edge 7 of the container 2 is bonded to the edge of the tacky tape 4. When using the preparation, the sheet 3 is broken to impregnate the supporting sheet 5 with the solution in the container 2. The container 2 is peeled and the supporting sheet 5 containing the drug is subsequently applied to skin.
Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) at least 10 hours per day for 8 -0/+3 days. A fresh pair of lenses will be worn each day.
This study is to determine the effect of flipped learning model on blood pressure knowledge level and self-directed learning skills of first-year nursing students.

This study was a pre-post test open-label randomized controlled trial. Settings and Participants: This research was conducted with 94 first-year students (experimental group = 48, control group = 46) studying at a university in Turkey, Faculty of Health Sciences, Department of Nursing. The students were divided into experimental and control groups using a simple randomization method. The study data were collected using the Descriptive Characteristics Form, the Blood Pressure Knowledge Test, and the Self-Managed Learning Skills Scale. The students in the experimental group were trained using the flipped learning model. The students in the control group were trained using only a traditional education method.
Attitudes determine our behaviour to some extent. Health professionals should have a global perspective of disability. They must provide treatment to people with disability and care for them, but also should accept them with no judgements or discrimination. The general objective of this study is to know the attitude towards people with disability of Nursing and Physiotherapy students in the University of Cadiz. Method: This is a descriptive, correlational, transversal and synchronous study. A total of 200 students participate in the study (91 from the Bachelor's Degree in Nursing and 109 from the Bachelor's Degree in Physiotherapy). The 'Attitudes towards people with disability Scale' was used.
This study is aimed to observe the efficacy and safety of the Chidamide Plus Cladribine regimen in treating patients with refractory or relapsed AML. Patients must provide written informed consent and meet all the inclusion criteria and none of the exclusion criteria to be eligible. The eligible patients with refractory or relapsed AML will receive chidamide plus cladribine regimen. Response criteria will be assessed according to the guidelines of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in AML. In case of partial remission, the second identical course will be started. In case of complete remission, allogeneic hematopoietic stem cell transplantation will be performed if available. Patients without complete remission after two courses of treatment will be withdrawn from the study.
Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
The recent article by Harit et al. in Human Genomics reported a novel association of the C allele of rs479200 in the human EGLN1 gene with severe COVID-19 in Indian patients. The gene in context is an oxygen-sensor gene whose T allele has been reported to contribute to the inability to cope with hypoxia due to increased expression of the EGLN1 gene and therefore persons with TT genotype of EGLN1 rs479200 are more susceptible to severe manifestations of hypoxia. In contrast to this dogma, Harit et al. showed that the C allele is associated with the worsening of COVID-19 hypoxia without suggesting or even discussing the scientific plausibility of the association. The article also suffers from certain epidemiological, statistical, and mathematical issues that need to be critically elaborated and discussed. In this context, the findings of Harit et al. may be re-evaluated.
Autologous chondrocyte implantation using collagen membrane (ChondroGide) Please see reference 1 and 2 for details regarding ACI. In this study we are using the collagen membrane instead of periosteum- the other details are exactly the same as in our previous RCT.
Apatinib, 250mg, once a day (qd), take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.According to the patient's condition, a single drug was selected for 6 cycles of chemotherapy in gemcitabine, yew and ruibin, changchun. After the chemotherapy, the single drug apatinib was maintained.Adverse reactions should be closely monitored during the use of apatinib and adjusted as needed to enable patients to tolerate treatment. The adverse reactions caused by apatinib can be treated by symptomatic treatment, drug withdrawal and dose adjustment. In clinical studies, dose adjustment usually occurs in the second and third cycles (28 days is one cycle). In case of 3/4 grade adverse reactions, the drug can be suspended until the toxic and side effects are completely recovered. Exit the study if 3/4 level of adverse reactions occur again after resumption of medication.
A minority of initial multiple sclerosis (MS) presentations clinically or radiologically resemble other central nervous system (CNS) pathologies, acute disseminated encephalomyelitis (ADEM) or tumefactive demyelination (atypical demyelination presentations). With the aim of better defining the long-term outcomes of this group we have performed a retrospective cohort comparison of atypical demyelination versus 'typical' MS presentations. Twenty-seven cases with atypical presentations (both first and subsequent demyelinating events) were identified and compared with typical MS cases. Disease features analysed included relapse rates, disability severity, whole brain and lesion volumes, lesion number and distribution. Atypical cases represented 3.9% of all MS cases. There was considerable overlap in the magnetic resonance imaging (MRI) features of ADEM-like and tumefactive demyelination cases. ADEM-like cases tended to be younger but not significantly so. Atypical cases showed a trend towards higher peak expanded disability severity score (EDSS) score at the time of their atypical presentation. Motor, cranial nerve, cerebellar, cerebral and multifocal presentations were all more common in atypical cases, and less likely to present with optic neuritis. Cerebrospinal fluid (CSF) white cell counts were higher in atypical cases (p = 0.002). One atypical case was associated with peripheral blood myelin oligodendrocyte glycoprotein (MOG) antibodies, but subsequent clinical and radiological course was in keeping with MS. There was no difference in long-term clinical outcomes including annualised relapse rates (ARR), brain volume, lesion numbers or lesion distributions. Atypical demyelination cases were more likely to receive high potency disease modifying therapy early in the course of their illness. Despite the severity of initial illness, our cohort analysis suggests that atypical demyelination presentations do not confer a higher risk of long-term adverse outcomes.
Phase I Dose Level 1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. One dose (400 mg/m2 IV) of Erbitux was given prior to start of radiation, then weekly at 250 mg/m2 IV. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
Phloroglucinol (PG) is one of the abundant isomeric benzenetriols in brown algae. Due to its polyphenolic structure, PG exhibits various biological activities. However, the impact of PG on anagen signaling and oxidative stress in human dermal papilla cells (HDPCs) is unknown. In this study, we investigated the therapeutic potential of PG for improving hair loss. A non-cytotoxic concentration of PG increased anagen-inductive genes and transcriptional activities of β-Catenin. Since several anagen-inductive genes are regulated by β-Catenin, further experiments were performed to elucidate the molecular mechanism by which PG upregulates anagen signaling. Various biochemical analyses revealed that PG upregulated β-Catenin signaling without affecting the expression of Wnt. In particular, PG elevated the phosphorylation of protein kinase B (AKT), leading to an increase in the inhibitory phosphorylation of glycogen synthase kinase 3 beta (GSK3β) at serine 9. Treatment with the selective phosphoinositide 3-kinase/AKT inhibitor, LY294002, restored the increased AKT/GSK3β/β-Catenin signaling and anagen-inductive proteins induced by PG. Moreover, conditioned medium from PG-treated HDPCs promoted the proliferation and migration of human epidermal keratinocytes via the AKT signaling pathway. Subsequently, we assessed the antioxidant activities of PG. PG ameliorated the elevated oxidative stress markers and improved the decreased anagen signaling in hydrogen peroxide (H2O2)-induced HDPCs. The senescence-associated β-galactosidase staining assay also demonstrated that the antioxidant abilities of PG effectively mitigated H2O2-induced senescence. Overall, these results indicate that PG potentially enhances anagen signaling and improves oxidative stress-induced cellular damage in HDPCs. Therefore, PG can be employed as a novel therapeutic component to ameliorate hair loss symptoms.
FIELD: medical industry. ^ SUBSTANCE: invention covers flexible press-formed intravaginal ring consisting of essentially homogeneous pressed mixture including polymethacrylate, plasticizing agent, gellatant and active agent. Gellant concentration in the mixture constitutes 2-20% of flexible press-formed intravaginal ring mass. Glass transition temperature of polymethacrylate is 10-50C. Production method of a flexible press-formed intravaginal ring is as follows: ^ a. Polymethacrylate at glass transition temperature, plasticizing agent, gellatant and active agent are mixed at the temperature higher than polymethacrylate glass transition temperature with further generation of a homogeneous mixture. ^ b. Pressing of the essentially homogeneous mixture at the temperature lower than mixture glass transition temperature with further production of a flexible press-formed intravaginal ring. ^ A production unit for flexible press-formed intravaginal rings comprises process compressing unit including a press mold with loading of the essentially homogeneous mix into it, upper mold, bottom mold and core rod for mixture pressing between the upper and the bottom molds for further production of a flexible press-formed intravaginal rings. After pressing the upper and the bottom molds are separated and a flexible press-formed intravaginal ring is pushed from the press mold. Thus, an end product is produced according to the invention. ^ EFFECT: preservation of active agents in the human upper tract for a long period of time due to which maximum and steady absorption of an active agent is possible at desired localization within the corresponding tract. ^ 29 cl, 16 dwg, 1 tbl, 1 ex
<P>PROBLEM TO BE SOLVED: To obtain a cell that is stably supplied and induced to an osteoblast and to provide a method for forming an osteoblast by using the same.  <P>SOLUTION: The cell that exists in a human amniotic epithelial cell layer and is differentiated and induced into an osteoblast is obtained. The method for forming an osteoblast comprises culturing a cell contained in a human amniotic epithelial cell layer in an osteoblast differentiation medium and inducing an osteoblast. Since the cell is derived from a human amnion and the human amnion is a large tissue and is treated as a medical waste after childbirth, the human amnion is stably supplied. The cell or the osteoblast derived from it is transplanted to the deleted part of a bone to restore the bone.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND: Training in delicate spinal dura mater suturing techniques poses significant challenges due to patient safety and medicolegal concerns, driving the need for alternative training methods beyond traditional mentorship models. This study aimed to introduce and validate a training model for orthopaedic residents using perfusion-based porcine spines to simulate intraoperative durotomy and subsequent repair.
METHODS: Nine junior orthopaedic residents were invited to participate. Three attending orthopaedic spine surgeons were included in the control group. Fresh porcine spines were used for the simulation, and a perfusion-based system was implemented to replicate cerebrospinal fluid circulation and apply hydrostatic pressure to the dura. Durotomies were made and mended with 6-0 prolene sutures, and the participants' performance was assessed across six trials for repair speed and leakage pressure. Additionally, the self-confidence levels of the residents were analyzed before and after the training.
RESULTS: While attending surgeons showed consistent performance across trials, residents demonstrated a 70% reduction in mean total time and a 62% increase in mean leakage pressure after training. Residents showed significant improvements in repair speed from Trial 4 and in repair quality from Trial 3 compared with Trial 1 as the baseline. The difference compared with attending surgeons became insignificant in repair speed from Trial 4 and in repair quality from Trial 2, indicating that the residents' performance approached that of the attending surgeons. Residents' self-confidence increased significantly from a mean pre-training score of 1.1 to a mean post-training score of 4.3.
CONCLUSIONS: This simulation model, which utilizes fresh porcine spines and a perfusion-based system, is an accessible, cost-effective, and high-fidelity training method for dural repair during spinal surgery.
Neutrophils represent one of the host's first lines of defense against invading pathogens. However, an aberrant activation can cause damage to the host. In the case of respiratory infections with viral or bacterial pathogens, one of the most common complications is the development of acute respiratory distress syndrome, in which neutrophil infiltration into the lung is a hallmark. Neutrophils gain expression of chemokine receptors under inflammatory conditions, and their activation can amplify the neutrophil responses. Earlier studies showed that neutrophils recruited to the lung mucosa during bacterial infection upregulate expression of CCR3 and ex vivo stimulation of CCR3 results in an increased neutrophil activation. Therefore, the modulation of effector functions or migration of neutrophils to target sites through chemokine receptors constitutes an opportunity for pharmacological intervention. We aimed to determine whether the blockade of the CCR3 using the specific antagonist SB-328437 reduces neutrophil recruitment and inflammation in the lung in the lipopolysaccharide (LPS)-induced lung injury model and influenza infection in mice. We found that neutrophils acquire CCR3 expression in the lung alveolar space. The intraperitoneal administration of SB-328437 reduced neutrophil recruitment to the lung alveolar space and reduced tissue damage in both the LPS-induced lung injury model and influenza infection. Moreover, treatment with SB-328437 reduced the percentage of neutrophils producing TNFα and neutrophil activation in the alveolar space. Together, these data suggest that CCR3 blockade might be a pharmacological strategy to prevent the aberrant neutrophil activation that results detrimental for the host but preserves sufficient effector response to control the pathogen.